A recent study conducted by CIBS researchers and published in the Journal of the American Medical Association (JAMA) found that among patients with breast cancer, tamoxifen and steroidal aromatase inhibitors were associated with a decrease in the number who received a diagnosis of neurodegenerative disease (NDD), specifically Alzheimer’s and dementia.
These findings not only advance knowledge and our ability to prevent, treat and cure cancer, but increase the importance of understanding the long-term outcomes of therapy selection for age-related neurodegenerative diseases.
The fact that breast cancer is the second most common cancer in women (after skin cancer) and that women are disproportionately affected by Alzheimer’s disease and related dementia provide a unique opportunity to reduce the global disease burden of neurodegenerative diseases.
Read the full investigation at JAMA Network | Open: https://bit.ly/2UAdOUn